NBIX Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. (NBIX) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 100% planned / 0% discretionary
Largest single sale: $37.8M.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| ABERNETHY MATT | Chief Financial Officer | Sell 10b5-1 | 2,311 | $157.20 | $363.3K | 42,808 −5.1% of holding | |
| Boyer David W. | Chief Corp. Affairs Officer | Sell 10b5-1 | 826 | $157.45 | $130.1K | 8,722 −8.7% of holding | |
| BENEVICH ERIC | Chief Commercial Officer | Sell 10b5-1 | 2,154 | $154.61 | $333.0K | 64,408 −3.2% of holding | |
| Norwalk Leslie V | Director | Sell 10b5-1 | 1,250 | $182.01 | $227.5K | 1,588 −44% of holding | |
| Delaet Ingrid | Chief Regulatory Officer | Sell 10b5-1 | 4,367 | $181.02 | $790.5K | 16,225 −21.2% of holding | |
| Lippoldt Darin | Chief Legal Officer | Sell 10b5-1 | 10,000 | $179.60 | $1.8M | 54,729 −15.4% of holding | |
| Delaet Ingrid | Chief Regulatory Officer | Sell 10b5-1 | 8,433 | $178.72 | $1.5M | 16,225 −34.2% of holding | |
| Delaet Ingrid | Chief Regulatory Officer | Sell 10b5-1 | 2,737 | $178.54 | $488.7K | 16,225 −14.4% of holding | |
| Delaet Ingrid | Chief Regulatory Officer | Sell 10b5-1 | 3,401 | $178.57 | $607.3K | 16,225 −17.3% of holding | |
| Lippoldt Darin 2 fills | Chief Legal Officer | Sell 10b5-1 | 9,800 | $170.16 | $1.7M | 54,729 −15.2% of holding | |
| Lippoldt Darin | Chief Legal Officer | Sell 10b5-1 | 200 | $169.56 | $33.9K | 54,729 −0.4% of holding | |
| SHERWIN STEPHEN A 5 fills | Director | Sell 10b5-1 | 25,000 | $165.32 | $4.1M | 32,977 −43.1% of holding | |
| Norwalk Leslie V | Director | Sell 10b5-1 | 1,250 | $168.06 | $210.1K | 2,838 −30.6% of holding | |
| Cooke Julie 5 fills | Chief Human Resources Officer | Sell 10b5-1 | 36,937 | $156.22 | $5.8M | 45,097 −45% of holding | |
| Onyia Jude | Chief Scientific Officer | Sell 10b5-1 | 11,000 | $160.25 | $1.8M | 25,846 −29.9% of holding | |
| Delaet Ingrid | Chief Regulatory Officer | Sell 10b5-1 | 2,261 | $156.71 | $354.3K | 16,225 −12.2% of holding | |
| Onyia Jude | Chief Scientific Officer | Sell 10b5-1 | 11,000 | $155.53 | $1.7M | 25,846 −29.9% of holding | |
| Boyer David W. | Chief Corp. Affairs Officer | Sell 10b5-1 | 3,888 | $156.64 | $609.0K | 7,799 −33.3% of holding | |
| GORMAN KEVIN CHARLES | Director | Sell 10b5-1 | 245,088 | $154.33 | $37.8M | 511,293 −32.4% of holding | |
| POPS RICHARD F | Director | Sell 10b5-1 | 15,000 | $157.65 | $2.4M | 34,480 −30.3% of holding | |
| Norwalk Leslie V | Director | Sell 10b5-1 | 3,810 | $155.01 | $590.6K | 2,429 −61.1% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.